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In the last few years, the development of a plasmid-based reverse genetics system for mammalian
reovirus has allowed the production and characterization of mutant viruses. This could be especially
signiﬁcant in the optimization of reovirus strains for virotherapeutic applications, either as gene vectors
or oncolytic viruses. The genome of a mutant virus exhibiting increased sensitivity to interferon was
completely sequenced and compared with its parental virus. Viruses corresponding to either the
parental or mutant viruses were then rescued by reverse genetics and shown to exhibit the expected
phenotypes. Systematic rescue of different viruses harboring either of the four parental genes in a
mutant virus backbone, or reciprocally, indicated that a single amino acid substitution in one of λ2
methyltransferase domains is the major determinant of the difference in interferon sensitivity between
these two viruses.
& 2015 Elsevier Inc. All rights reserved.
Introduction
Mammalian reoviruses are among a plethora of viruses that are
presently under investigation for their ability to preferentially
infect and destroy transformed/cancer cells. This has led to recent
progress in their clinical use against various forms of human
cancers (brieﬂy reviewed among others by Kelly et al., 2009;
Black and Morris, 2012). In contrast to most other “oncolytic”
viruses presently under consideration for clinical use, reoviruses
are naturally oncolytic and have not been submitted to genetic
manipulation for their clinical use. In fact, it was not possible until
recently (Kobayashi et al., 2007) to easily manipulate the reovirus
genome using a plasmid-based reverse genetics system.
The initial observations that led to the utilization of reovirus as an
“oncolytic” virus suggested that a decreased activity of the
interferon-inducible double-stranded RNA-dependent protein kinase
(PKR), which occurs upon Ras-induced cell transformation, was
responsible for the preferential infection and destruction of cancer
cells by reovirus (Strong et al., 1998). Despite the fact that multiple
steps of the reovirus replicative cycle are likely involved in prefer-
ential replication and virus-induced cancer cell death (Lemay et al.,
2007; Marcato et al., 2007), further work has supported the idea that
a lower induction of interferon in Ras-transformed cells favors viral
propagation and could be of major importance to the virus' oncolytic
activity (Shmulevitz et al., 2010).
To further support the idea that interferon-induced antiviral path-
ways are critical in the ability of reovirus to discriminate between
parental and Ras-transformed cells, a mutant virus obtained by
chemical mutagenesis was selected for its increased sensitivity to
interferon and was actually shown to exhibit a more complete
blockage than the wild-type virus in parental cells, even at extremely
high multiplicity of infection (Rudd and Lemay, 2005).
Multiple reovirus genes are suspected to be involved in the
control of the interferon innate immune response (Sherry, 2009;
Sherry et al., 2009). The μ2 protein was shown to be the major
determining factor in the control of interferon signaling induction
by altering the subcellular localization of IRF-9 (Irvin et al., 2012;
Zurney et al., 2009). The σ3 protein could rather affect interferon
sensitivity due to its ability to sequester the dsRNA activator of the
interferon-inducible protein kinase PKR; however, this property of
σ3 could be modulated by μ1 since the σ3-μ1 heterohexamer does
not appear to bind dsRNA (Schiff, 2008). Finally, at least in some
cell types, the σ2 and λ2 protein were previously suspected to play
a role in the control of either induction of interferon signaling or
virus' sensitivity to interferon (Sherry et al., 1998).
In order to clarify which genetic determinants are involved in
the large difference in interferon sensitivity between the parental
and previously identiﬁed P4L-12 mutant virus (Rudd and Lemay,
2005), the complete sequence of the viral genome was deter-
mined. Both viruses were then reconstructed by site-directed
mutagenesis and reverse genetics, since a number of differences
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were observed between the isolate used to construct the reverse
genetics plasmids and the parental laboratory stock initially used
to isolate the mutant virus. Each four genes exhibiting differences
between the parental and mutant viruses were then individually
substituted either to replace the mutant gene by its parental
counterpart or replacing the parental gene by its mutant counter-
part in the parental background. This clearly demonstrated that
the single amino acid substitution in one of the two methyltrans-
ferase domains of λ2 is the major determinant of the difference in
interferon sensitivity between these two viruses.
Results
Sequencing of the interferon-sensitive P4L-12 mutant
In order to determine the differences in sequence between the
interferon-sensitive P4L-12 mutant (Rudd and Lemay, 2005) and
the original wild-type type 3 Dearing (T3D) (T3/Human/Ohio/
Dearing/55) from which it was derived, the whole coding
sequence of the genome was analyzed by RT-PCR on the semi-
puriﬁed viral genome from both the mutant and wild-type
laboratory stocks, followed by direct sequencing of the PCR
products, as described in Section Materials and Methods and
previously used in the laboratory (Jabre et al., 2013).
Despite the fact that the P4L-12 mutant was obtained following
treatment with a high dose of the chemical mutagen nitrosogua-
nidine (Rudd and Lemay, 2005), only 4 genes were found to
exhibit nonsynonymous mutations compared to the wild-type
resulting in a total of 6 amino acids substitutions (Table 1). Of
these, only the λ2 T636M, μ1 P315S and σ3 M221I are unique
among currently available sequences of T3D (Table 2 and data not
shown) and were thus of special interest. Six additional silent
nucleotide substitutions were also found between the wild-type
and mutant virus (GeneBank accession numbers KP208804 to
KP208813 for the wild-type and KP208814 to KP208823 for P4L-
12 mutant).
Sequence comparison of different stocks of wild-type reovirus type
3 Dearing
The complete sequences obtained were also compared with
that of the wild-type virus encoded by the 10 plasmids of the
reverse genetics system (Kobayashi et al., 2007) and at least one
amino acid change between the two wild-type viruses was found
in seven out of 11 proteins; the only completely identical proteins
were σ2, σ3, σNS and σ1s. This is not the ﬁrst time that such
differences were observed between laboratory stocks of so-called
reovirus type 3 Dearing (Coffey et al., 2006; Nygaard et al., 2013;
Yin et al., 2004), this has even lead to the designation of subtypes
such as T3DF (from Fields' laboratory), T3DN (from Nibert's
laboratory) and T3DC (from Cashdollar's laboratory). Thus, for sake
of simplicity, the laboratory virus stock used in the present study
will be referred to as T3DS (Sandekian) while the wild-type virus
rescued from the plasmids originally obtained from Kobayashi and
Dermody will be referred to as T3DK (Kobayashi). In addition to the
12 amino acid substitutions, 11 silent nucleotide substitutions
between the two viruses were also found (data not shown).
Comparative sequence analysis was also performed with the
sequence of another complete T3D genome (referred to as T3DW)
that was used in a recent study by another group (van den
Wollenberg et al., 2012) and the sequence of another laboratory
stock deposited in the NCBI database by one further group
(referred to as T3DH); ﬁnally the sequence of the virus currently
used in oncolytic virotherapy under the tradename “REOLYSINs”
was added to the comparison (Chakrabarty et al., 2014). Only
complete sequences determined by direct sequencing of the viral
genome were retained for this analysis since it is difﬁcult to
assume that sequences obtained earlier from cloned viral genes
are necessarily representative and that they would actually gen-
erate a replication-competent virus when combined together.
The laboratory subtype, T3DS, did not display any more differ-
ences from T3DK when compared to other completely sequenced
genomes. While some positions are clearly more variable, all
stocks showed the presence of 8 to 19 differences including 2–8
Table 1
Amino acids differences between wild-type reovirus type 3 Dearing laboratory
stock (T3DS) and derived mutant P4L-12.
Wild-type (T3DS) Mutant (P4L-12) Amino acid position
λ2 T M 636
μ1 P S 315
T A 449
μNS V A 705
σ3 G E 198
M I 221
Table 2
Amino acids differences between different reovirus type 3 Dearing.
T3DKa T3DSb T3DWc T3DHd Reolysine Amino acid position
λ3 M L 979
S R 1045
N S S S 1048
S P 1186
λ2 G E E E 504
G R 509
I M M 1165
λ1 A T 201
I S S S 500
A T 574
Q H 852
M V 982
G D 1017
μ2 A V 122
S P P P 208
R Q Q Q Q 342
A S 528
μ1 E D 73
T I 142
A V V 305
– R R 439
A V V 440
Q M M 441
A T 449
A T 529
μNS K E E E 180
A V V 705
G D 707
σ1 V A 22
T I 249
Y S 253
T A A A 408
σ3 W R 133
G K 198
E D D D 229
a T3D-Kobayashi, wild-type virus from the reverse genetics system (Kobayashi
et al., 2007).
b T3D-Sandekian, original wild-type virus reported in this study
c T3D-Wollenberg, wild-type virus (R124) used in van den Wollenberg et al.
(2012).
d T3D-Hosseini, wild-type unpublished virus sequence from NCBI database.
e T3D-Reolysins, wild-type virus used in clinical trials as described in
Chakrabarty et al. (2014).
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unique substitutions compared to T3DK. It thus seems that each
stock, or subtype, has its own sequence “signature” and that T3DS
with 12 amino acid differences including only 3 unique substitu-
tions is not more divergent from T3DK than other virus stocks
currently in use in different laboratories.
Reverse genetics rescue of viruses harboring single-gene substitution
In order to determine which of the amino acids differences
between T3DS and P4L-12 viruses are responsible for the difference
in interferon sensitivity between the two viruses, site-directed muta-
genesis was used to introduce the changes in the reverse genetics
plasmids encoding the different proteins; whenmore than one change
was found on the same protein, the corresponding nucleotide changes
were all introduced on the same plasmid. Since the parental T3D
(T3DS) used to isolate P4L-12 differs from the plasmid-encoded T3DK
sequence, a complete set of plasmids encoding “wild-type” T3DS was
ﬁrst constructed and then further subjected to site-directed mutagen-
esis to obtain P4L-12 encoding sequences.
Both a parental T3DS and P4L-12 virus were rescued by
transfection of the corresponding plasmid combination. Viruses
were similarly obtained using one P4L-12 gene (L2, M2, M3 and
S4) in a background of nine T3DS genes. All these viruses were
rescued and propagated, as described in Materials and methods.
Reciprocally, viruses harboring one T3DS gene in a background of
nine P4L-12 genes were also rescued and propagated.
The infectivity and replicative ability of these different viruses
was then examined. L929 cells were infected at a multiplity of
infection of 2 TCID50 units per cell and viral proteins in infected
cells were ﬁrst examined by immunoblotting (Fig. 1A); this was a
ﬁrst indication that all viruses were able to infect with a similar
efﬁciency since there were no apparent differences in the amount
of viral proteins produced. Production of infectious virus was next
examined by infecting cells and measuring the fold-increase of
infectious virus (Fig. 1B). In either the T3DS or P4L-12 background,
all viruses harboring substitution of single genes from the other
virus did not appear to be signiﬁcantly different from their back-
ground virus. In the T3DS background a small increase (up to
approximately sixfold for the S4 substitution) was observed while
in the P4L-12 background a twofold increase was observed for M2
and twofold decrease for S4. Overall, there was thus no apparent
signiﬁcant defects when single genes were substituted in either
background.
Interferon sensitivity of rescued viruses
Having established that the different rescued viruses can
replicate to similar levels in the absence of interferon, their
interferon sensitivity was then examined in comparison with their
respective parental viruses.
Interferon sensitivity was ﬁrst examined by measuring the titer
reduction on L929 cells treated at a ﬁxed, near saturating, β-
interferon concentration (200 international units/ml), as described
in Materials and methods. As expected, rescued T3DS harboring
none of the P4L-12 genes exhibited resistance to interferon, its
titer being almost unaffected at 200 international units/ml of
interferon while rescued P4L-12 showed close to a hundred-fold
decrease of its titer (Fig. 2). These values are comparable with
those routinely obtained with the two parental viruses in previous
experiments (data not shown).
Substitution of T3DS genes by those encoding either μNS or μ1
of P4L-12 only slightly increased sensitivity to interferon by less
than tenfold while σ3 had no effect (Fig. 2). However, substitution
of the L2 gene encoding λ2 signiﬁcantly increased the interferon
sensitivity rendering the virus as sensitive as the P4L-12 virus. The
reciprocal experiment where single genes from T3DS were singly
Fig. 1. Infectivity and replication of the different rescued viruses. L929 cells were infected at a MOI of 2 TCID50 units/cell. Results for the different viruses harboring either
none or single P4L-12 genes in a T3DS background or none or single T3DS genes in a P4L-12 background are presented. (A) Proteins were recovered from infected cells at 24 h
and analyzed by immunoblotting using an anti-σ3 monoclonal antibody, as described in Section Material and methods. (B) Infected cells were recovered at either 24 or 48 h
post-infection. Cells were disrupted by three cycles of freeze–thaw (80 1C to room temperature) and virus titration was performed by TCID50 on L929 cells in 96-well
microplates. Results, on a logarithmic scale with error bars representing standard error of the mean, are presented as the average fold-increase in two distinct experiments at
24 h, 48 h, and with all four data points combined, as indicated.
V. Sandekian, G. Lemay / Virology 483 (2015) 229–235 231
substituted in the P4L-12 background conﬁrmed that λ2 by itself is
sufﬁcient to render the virus as resistant as T3DS while other
proteins had only a slight (μNS) or essentially no effect (μ1 and σ3)
on interferon sensitivity (Fig. 2).
It appears very unlikely that differences in residual interferon
in the viral inocula could affect the results, given the freeze-thaw
treatment, dilutions used, and the fact that there was no differ-
ences in interferon induction between T3DS and P4L-12 (data not
shown). However, in order to further ruled out this possibility,
infectious T3DS, P4L-12 and single L2 reassortant viruses were
recovered from human HeLa cells before being titrated on murine
L929 cells in the presence or absence of murine interferon; in
these conditions any interferon from virus inoculum will be of
human origins and will not act on murine cells used in the
interferon assay. Identical results were obtained, correlating the
presence of L2 from P4L-12 with interferon sensitivity (data not
shown).
The interferon sensitivity of the same viruses was then further
examined using serial binary dilutions of interferon in 96-multiwell
plates that were then stained and quantitated (Fig. 3A). When the
rescued T3DS virus and viruses harboring a single P4L-12 gene in this
background were examined (left panel), the effect of λ2 was again
evident, especially at intermediate concentrations of interferon
(approximately 10 to 50 IU/ml) while μNS and σ3 had no effect. In
this assay, at lower interferon concentrations compared to Fig. 2, the
μ1 protein of P4L-12 also increased interferon sensitivity.
When viruses harboring single T3DS genes in a P4L-12 back-
ground were similarly analyzed (Fig. 3A, right panel), only λ2 clearly
affected interferon sensitivity, rendering the virus as resistant to
interferon as T3DS. The change in interferon sensitivity conferred by
M2 of P4L-12 in the T3DS background was not reciprocal; therefore it
was not further examined in the present study.
Altogether, the effect of λ2 was thus most striking and this gene
appears to be the main and most likely the only determinant of
the difference in interferon sensitivity between T3DS and P4L-12,
its presence being clearly sufﬁcient to reconstitute the respective
phenotype of the two viruses. A representative multiwell plate is
presented (Fig. 3B) comparing the original T3DS and P4L-12 virus
with their corresponding rescued virus and those where the L2
gene was singly substituted.
Expression of the λ2 protein in infected cells
In order to rule out the possibility that there is a difference in
the amount of λ2 present in the infected cells during infection by
T3DS or P4L-12, immunoblotting was performed on the rescued
viruses harboring all the genes of either viruses, as well as on the
viruses harboring solely the λ2 protein of the other virus (T3DS
background with λ2 of P4L-12 and reciprocally). The amount of λ2
protein in each case was compared with that of the major outer
capsid protein μ1. There was no apparent difference between these
four viruses (Fig. 3C) and a simple change in λ2 expression or
stability is thus unlikely.
Discussion
The present study illustrates that the state-of-the-art plasmid-
based reverse genetics approach can be successfully used to study
and completely reconstruct virus mutants previously identiﬁed by
the use of more classical genetic techniques such as chemical
mutagenesis. This has allowed to identify polymorphic amino
acids residues in the mammalian orthoreovirus genome as well
as clearly pinpoint an amino acid substitution that can drastically
affect the interferon sensitivity of viral strains. As previously
mentioned, the λ2 protein was previously identiﬁed by classical
reassortment studies as a possible molecular determinant of the
control of interferon response in reovirus-infected cells; however,
this is the ﬁrst time that this has been ﬁrmly established using a
completely deﬁned genetic system. Interestingly, an immunore-
ceptor tyrosine-based activation motif (ITAM) that could affect
interferon signaling pathways in some cell types, is observed in λ2,
although there is currently no evidence that it is actually func-
tional (Stebbing et al., 2014). The amino acid substitution in P4L-12
is not part of this ITAM motif.
The threonine at position 636, substituted for a methionine in
P4L-12, is a conserved residue in the λ2 protein sequence of
different virus strain (Table 2) (Breun et al., 2001) and is located
in one of the two methyltransferase domains (Reinisch et al.,
2000; Breun et al., 2001; Bujnicki and Rychlewski, 2001). It is still
not ﬁrmly established if this ﬁrst methyltransferase domain is
responsible for N-7 or the subsequent 20-O methylation of the cap
structure. However, sequence comparisons suggest the latter
possibility (Bujnicki and Rychlewski, 2001) and is also consistent
with the relative order of the two methyltransferase domains in
Cypovirus (Zhu et al., 2014), another double-stranded RNA virus of
the Reoviridae family. Methylation of the RNA cap structure, espe-
cially at the 20-O position could be of importance to avoid recogni-
tion of viral RNA as nonself. It could thus affect either induction
of interferon signaling or sensitivity to interferon-induced antiviral
Fig. 2. Interferon sensitivity of the different rescued viruses. The different rescued viruses, as in Fig. 1, were titrated using a TCID50 assay in the absence or presence of
200 IU/ml of murine β-interferon, as described in Section Material and methods. Average fold-reduction in virus titers for independent experiments for each sample is
presented on a logarithmic scale with error bars indicating the maximal value observed for each virus (n¼5 for the parental viruses, n¼3 for the two viruses harboring
substitution of the L2 gene and n¼2 for the other viruses). In both the T3DS and P4L-12 background, only L2 gene substitution statistically altered interferon sensitivity, at
p¼0.002 and p¼0.05 respectively using unpaired Student's t-test.
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proteins, such as IFIT1 (recently reviewed by: Hyde and Diamond,
2015). This aspect has been especially well studied in members of
the Flaviviridae family but has also been noticed in such different
viruses as coronaviruses, vesicular stomatitis virus and metapneu-
movirus (Dafﬁs et al., 2011; Zust et al., 2011; Habjan et al., 2013;
Kimura et al., 2013; Dong et al., 2014; Kindler and Thiel, 2014; Ma
et al., 2014; Menachery et al., 2014). An altered 20-O methyltrans-
ferase activity of λ2 could thus potentially explain the altered
interferon resistance of P4L-12 compared to the parental virus.
Interestingly, in rotavirus, another member of the Reoviridae
family, the capping enzyme VP3 was shown to act as an antagonist
of innate immunity (Zhang et al., 2013) and it was proposed that
variations in the efﬁciency of the capping reaction, more speciﬁ-
cally that of methyltransferase activity, should be examined to
determine if it could affect the ability of the virus to control the
innate immune reaction (Arnold et al., 2013; Ogden et al., 2014). It
will be of interest to perform similar studies with the λ2 protein of
reovirus.
Previous work has established the μ2 protein as the major
determinant of the extent of interferon signaling following reo-
virus infection (Zurney et al., 2009; Irvin et al., 2012; Stebbing
et al., 2014). When interferon induction by T3DS and P4L-12 was
compared by recovering supernatant from L929-infected cells
(data not shown), both of these supernatants were able to
similarly protect cells against the unrelated murine encephalo-
myocarditis virus (EMCV), as used in previous studies (Sandekian
et al., 2013). This is well in accordance with the fact that there is no
difference in the μ2 protein of the two viruses and thus probably
no signiﬁcant differences in induction of either interferon or
interferon-induced genes. Furthermore, it should be stressed that
the presence of a proline at position 208 indicates that these
viruses are relatively, although not completely, efﬁcient at repres-
sing interferon signaling (Irvin et al., 2012; Stebbing et al., 2014)
suggesting that their difference could rather resides in differences
of sensitivity to interferon-induced antiviral mechanisms although
this remains to be ﬁrmly established.
The results presented herein thus further support the idea that
multiple reovirus proteins are involved as determinants of reo-
virus' sensitivity to interferon either by differences in the modula-
tion of interferon signaling or differences in the sensitivity of the
interferon-induced antiviral effectors. In this study the λ2-
encoding gene, L2, appears as the major determinant of the
difference between T3DS and P4L-12. The importance of multiple
regulatory mechanisms directed against the interferon innate
immune response has also been demonstrated in rotavirus
(Arnold et al., 2013), another member of the Reoviridae, and in
other unrelated viruses such as the large DNA virus vaccinia
(Perdiguero and Esteban, 2009) as well as important human RNA
viruses such as hepatitis C (Qashqari et al., 2013) and inﬂuenza
virus (Garcia-Sastre, 2011).
There are numerous evidence suggesting induction of inter-
feron antiviral response or virus' sensitivity to this response is
critical in the differential ability of a virus to replicate in, and kill,
different cell types. As described in the introduction, this is also
likely critical in reovirus' oncolytic ability. The possibility of
modulating both the level of interferon signaling and sensitivity
of reovirus strains to antiviral interferon-induced genes, by a
combination of various mutations in either σ3, μ2 and λ2, could
certainly contribute to further optimization of viral strains for
infection and killing of different cancer cell types.
Materials and methods
Cell lines and viruses
L929 mouse ﬁbroblasts were originally obtained from the
American type culture collection (ATCCs CCL-1™). The baby
Fig. 3. Effect of different doses of interferon on the rescued viruses. (A) L929 cells were seeded in 96-well microplates and were infected 24 h later at a MOI of 0.05
TCID50 unit/cell with the different rescued viruses. Following the one-hour adsorption period at 4 1C, serial twofold dilutions of interferon were added to each well, as
indicated. Cells were incubated 3 days before being ﬁxed, stained with methylene blue, and quantiﬁed as described in Section Materials and methods. A representative
experiment out of three independent experiments is presented. (B) Representative microwell plate comparing the two original T3DS and P4L-12 viruses with rescued viruses
rsT3DS and rsP4L-12, as well as P4L-12 harboring λ2 from T3DS, rsP4L-12-[L2-(T3DS)], and reciprocally T3DS harboring λ2 from P4L-12, rsT3DS-[L2-(P4L-12)]. (C) Proteins
were recovered 24 h post-infection from L929 cells infected at a MOI of 2 TCID50 unit/cell, as in panel B. Immunoblotting analysis was then performed using either anti-λ2 or
anti-μ1 monoclonal antibody, as described in Section Materials and methods.
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hamster kidney cell line (BHK) stably expressing the T7 RNA
polymerase has been described (Buchholz et al., 1999) and was a
generous gift from the laboratory of Dr John Hiscott (Lady Davis
Research Institute, Montréal, Canada). Both cell lines were grown
in minimal Eagle medium (MEM) with 5% fetal bovine serum.
Wild-type reovirus type 3 Dearing (T3/Human/Ohio/Dearing/
55) was originally obtained from the American Type Culture
Collection (Reovirus 3, ATCCs VR824™). The laboratory stock
was derived from a pure plaque after one passage of the original
stock on L929 cells. This laboratory virus stock was thereafter used
between passage 3 and 5 at a low multiplicity of infection.
Sequencing of the whole viral genomes
Viral genomic RNA was prepared and fragments for sequencing
were generated by RT-PCR, as previously described (Brochu-
Lafontaine and Lemay, 2012), except that Vertrel was used to
prepare reovirus virions (Mendez et al., 2000). The sequences
corresponding to all 10 genes of the wild-type laboratory stock
were deposited under accession numbers KP208804 to KP208813
in GenBank. The sequences corresponding to all 10 genes of the
reovirus interferon-sensitive P4L-12 mutant are accessible under
numbers KP208814 to KP208823.
Accession numbers for sequences used for comparisons are
EF494435 to EF494444 in the nucleotide database for T3DK;
ADJ00316 to ADJ00325 in the protein database for T3DH; and
GU991659 to GU991668 for T3DW in the nucleotide database. The
sequence of REOLYSINs was deduced from the differences noticed
between each of the genes and its reference sequence as described
(Chakrabarty et al., 2014).
Reverse genetics
The plasmids separately harboring each of the cDNA corre-
sponding to the 10 genes of reovirus serotype 3 Dearing, under the
transcriptional control of the T7 promoter, as previously described
(Kobayashi et al., 2007), were obtained from the laboratory of Dr
Terence Dermody (Vanderbilt University, Nashville, Tennessee). To
obtain virus mutants in speciﬁc genes, the corresponding plasmid
was directly submitted to site-directed mutagenesis and used to
recover infectious virus by transfection in BHK cells expressing the
T7 RNA polymerase and rescued viruses were propagated. Kinetics
of viral replication and viral titers were assessed as previously
described (Brochu-Lafontaine and Lemay, 2012).
Immunoblotting
Infected cells were recovered by scraping in a small volume of
medium and processed for immunoblotting, as previously described
(Brochu-Lafontaine and Lemay, 2012). Immunoblotting was per-
formed using monoclonal antibodies directed against either σ3
(4F2), λ2 (7F4) or μ1 (10F6) (Virgin et al., 1991). Images were obtained
using either autoradiography on Kodak BioMax Light ﬁlms or on a
Typhoon Trio™ imager (GE Healthcare Life Sciences).
Determination of interferon sensitivity
Interferon sensitivity was determined by two different approaches.
The reduction of titer assay was ﬁrst used as previously described
(Danis et al., 1997). Brieﬂy, L929 cells were seeded in 96-well plates
and were either left untreated or pre-treated with 200 international
units (IU)/ml of mouse β-interferon (PBL InterferonSource) for 24 h
before being used in virus titration by TCID50. Following virus
adsorption, interferon was added back to the pre-treated plate and
the reduction in virus titer in interferon-treated cells compared to
untreated cells was determined 7 days post-infection.
To measure sensitivity of viruses to different concentrations of
interferon, serial twofold dilution of interferon in 96-well plates
was done followed by infection with the different virus strains at
the same multiplicity of infection. Plates were stained with
methylene blue as previously described (Sandekian et al., 2013);
images were obtained and quantitated using an AlphaImager HP
image analyzer.
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